RNAZ Company Profile and Key Details
TransCode Therapeutics, Inc.
RNAZ Stock Price Chart
Stock Price Today
TransCode Therapeutics, Inc. (RNAZ) stock declined over -0.85%, trading at $3.49 on NASDAQ, down from the previous close of $3.52. The stock opened at $3.50, fluctuating between $3.46 and $3.61 in the recent session.
Stock Snapshot
Stock Price History Chart
Contact Details
About Company
TransCode Therapeutics, Inc., a biopharmaceutical company, engages in the development and commercialization of drugs and diagnostics for treating and identifying metastatic disease. Its lead therapeutic candidate, TTX-MC138, is a preclinical stage product for the treatment of metastatic cancer. The company's products in preclinical programs include TTX-siPDL1, an siRNA-based modulator of programmed death-ligand 1; TTX-siLIN28B, an siRNA-based inhibitor of RNA-binding protein LIN28B. Its cancer agnostic programs comprise TTX-RIGA, an RNAbased agonist of the RIG-I-driven immune response in the tumor microenvironment; TTX-CRISPR, a CRISPR/Cas9based therapy platform for the repair or elimination of cancer-causing genes inside tumor cells; and TTX-mRNA, an mRNA-based platform for the development of cancer vaccines meant to activate cytotoxic immune responses against tumor cells. The company was incorporated in 2016 and is based in Boston, Massachusetts.
Company Information
| Employees | 10 |
| Beta | 0.65 |
| Sales or Revenue | $0.00 |
| 5Y Sales Change% | 0% |
| Fiscal Year Ends | December |
| Sector | Healthcare |
| Industry | Biotechnology |
Frequently Asked Questions
TransCode Therapeutics, Inc. (NASDAQ: RNAZ) stock price is $3.49 in the last trading session. During the trading session, RNAZ stock reached the peak price of $3.61 while $3.46 was the lowest point it dropped to. The percentage change in RNAZ stock occurred in the recent session was -0.85% while the dollar amount for the price change in RNAZ stock was -$0.03.
The NASDAQ listed RNAZ is part of Biotechnology industry that operates in the broader Healthcare sector. TransCode Therapeutics, Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.
Mr. Thomas A. Fitzgerald M.B.A.
Chief Financial Officer, Vice President of Admin. & Director
Dr. Zdravka Medarova Ph.D.
Co-Founder, Chief Technology Officer & Member of Advisory Board
Dr. Anna Moore Ph.D.
Co-Founder, Scientific Advisor & Member of Scientific Advisory Board
Susan Duggan
Senior Vice President of Operations
Mr. Alan Freidman
Vice President of Investor & Client Relations
Ms. Susan Duggan M.B.A., R.N.
Senior Vice President of Operations
Dr. Qiyong Peter Liu Ph.D.
Vice President of Drug Discovery & Chief Scientist
Mr. Robert Michael Dudley
Co-Founder, Chief Executive Officer, Pres & Director
RNAZ's closing price is 31.2% higher than its 52-week low of $2.66 where as its distance from 52-week high of $66.33 is -94.74%.
Number of RNAZ employees currently stands at 10.
Official Website of RNAZ is: https://www.transcodetherapeutics.com
RNAZ could be contacted at phone 857 837 3099 and can also be accessed through its website. RNAZ operates from 6 Liberty Square, Boston, MA 02109, United States.
RNAZ stock volume for the day was 35.59K shares. The average number of RNAZ shares traded daily for last 3 months was 64.56K.
The market value of RNAZ currently stands at $2.43M with its latest stock price at $3.49 and 696.25K of its shares outstanding.
Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.
© 2025 Stocks Telegraph All rights reserved.
Most stock quote data provided by financialmodelingprep.com